Be ready for flu season

Help ensure correct coding and billing in your organization

Make sure you’ve done the following:

- Communicated which Seqirus flu vaccines your organization will use for the upcoming influenza season
- Educated staff on using product-specific CPT codes and NDCs for Seqirus vaccines and coding for administration
  Note: Visit flu.seqirus.com to access complimentary programs to help refresh your knowledge and stay up-to-date with correct coding and billing techniques.
- New
  FLUAD® QUADRIVALENT: CPT 90694
  Influenza virus vaccine, quadrivalent (allV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
- Unique CPT code for cell-based influenza vaccine
  FLUCELVAX® QUADRIVALENT: CPT 90674
  Influenza virus vaccine, quadrivalent (ccllV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
- Loaded appropriate CPT codes and NDCs in EHR

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “as is” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

Questions?

Call flu360 | Support for reimbursement support with Seqirus influenza vaccines
855-358-8966, option 3

Visit flu.seqirus.com to support your influenza immunization needs
FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

Important Safety Information

INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

• If Guillain–Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

ADVERSE REACTIONS

• The most common (≥10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see full Prescribing Information for FLUAD QUADRIVALENT here.

FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

FLUCELVAX® QUADRIVALENT (Influenza Vaccine)

Important Safety Information

INDICATION AND USAGE

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.

CONTRAINDICATIONS

• Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS & PRECAUTIONS

• Guillain–Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

ADVERSE REACTIONS

• The most common (≥10%) local and systemic reactions in children 6 through 8 years of age were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%), and myalgia (12%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see full Prescribing Information for FLUCELVAX QUADRIVALENT here.

FLUCELVAX QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

FLU360™, FLUAD® QUADRIVALENT, FLUCELVAX® QUADRIVALENT, and WE’VE GOT FLU COVERED™ are trademarks of Seqirus UK Limited or its affiliates.

© 2020 Seqirus USA Inc. July 2020 US/FLU360/0220/0001a